Group 1 - The company received a notification from its controlling shareholder, Shaanxi Century Xinyuan Commercial Management Co., Ltd., regarding the pledge of its shares on June 13, 2025 [1] - The pledged shares amount to 60,000,000, representing 9.74% of the shares held by the controlling shareholder and 2.68% of the total share capital of the company [1] - The pledge is for financing purposes and does not involve any lock-up shares [1] Group 2 - As of the announcement date, the total pledged shares by Century Xinyuan and its concerted actors amount to 718,645,251, which is 32.07% of the shares held by them and 68.16% of the total share capital of the company [2] - The financing amount corresponding to the pledged shares is 4.77 billion yuan, with 307,930,000 shares maturing within the next year, representing 49.98% of the shares held by the controlling shareholder [2] - The company states that there is no risk of forced liquidation for the pledged shares, and the controlling shareholder has a good credit status and strong repayment ability [2]

Group 1 - The high-pressure oxygen chamber concept declined by 2.26%, ranking among the top declines in concept sectors, with companies like Aoyang Health, International Medicine, and Weiao Co., Ltd. experiencing significant drops [1] - The main funds in the high-pressure oxygen chamber concept saw a net outflow of 363 million yuan, with seven stocks experiencing net outflows, led by Innovation Medical with a net outflow of 308 million yuan [2] - Other companies with notable net outflows include Aoyang Health, Dahu Co., Ltd., and Yinkang Life, with net outflows of 27.01 million yuan, 8.53 million yuan, and 6.79 million yuan respectively [2] Group 2 - The top gainers in concept sectors included the military equipment restructuring concept, which rose by 3.51%, and PCB concept, which increased by 3.29% [2] - The high-pressure oxygen chamber concept was among the sectors with the largest declines, alongside glyphosate and rare earth permanent magnets, which fell by 2.82% and 2.57% respectively [2] - The trading volume for the high-pressure oxygen chamber concept stocks showed varying turnover rates, with Innovation Medical at 36.76% and Aoyang Health at 17.53% [2]

证券代码：000516 证券简称：国际医学 公告编号：2025-029 西安国际医学投资股份有限公司 关于控股股东进行股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）的通 知，2025年6月13日，世纪新元将其持有的本公司无限售条件流通股 6,000万股股票与深圳市招商平安资产管理有限责任公司进行了融资类 质押，具体事项如下： 二、控股股东及其一致行动人股份累计质押的基本情况 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | 股东 | 持股数量 | 持股 | 本次质 | 本次质 | 占其 | 占公 | 已质押股份 | 未质押股份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | （股） | 比例 | 押前质 | 押后质 | 所持 | 司总 | 情况 | 情况 | 1 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 质押股份 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-028 西安国际医学投资股份有限公司 关于2022年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 性股票共计 2,181,562 股，占回购注销前公司总股本的 0.0973%，回购价款总计为 公司深圳分公司办理完成注销手续。本次回购注销完成后，公司总股本由 一、2022 年限制性股票激励计划审批及实施情况 次会议审议通过了《<2022 年限制性股票激励计划（草案）>及其摘要》等相关议 案，公司独立董事发表了独立意见，监事会对 2022 年限制性股票激励计划发表了 核查意见。 予以公示，公示时间为 2022 年 9 月 7 日至 2022 年 9 月 16 日。公示期满，公司监 事会未接到与激励计划拟激励对象有关的任何异议。具体内容详见公司于 2022 年 股票激励计划激励对象名单的审核及公示情况说明》。 年限制性股票激励计划（草案）>及其摘要》《2022 年限制性股票激励计划实施考 核管理办法》和《关于提请股东大会授权董事会办理公 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-028 西安国际医学投资股份有限公司 关于2022年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、西安国际医学投资股份有限公司（以下简称"公司"）本次回购注销限制 性股票共计 2,181,562 股，占回购注销前公司总股本的 0.0973%，回购价款总计为 12,783,953.32 元，涉及激励对象 108 人次。 2、截止 2025 年 6 月 13 日，上述限制性股票已在中国证券登记结算有限责任 公司深圳分公司办理完成注销手续。本次回购注销完成后，公司总股本由 2,241,078,315 股减少为 2,238,896,753 股。 一、2022 年限制性股票激励计划审批及实施情况 1、2022 年 9 月 6 日，公司第十二届董事会第八次会议、第十一届监事会第六 次会议审议通过了《<2022 年限制性股票激励计划（草案）>及其摘要》等相关议 案，公司独立董事发表了独立意见，监事会对 2022 年限制性股票激励计划发表了 ...

Core Viewpoint - The company refuted rumors regarding a significant number of expert departures, confirming that the information circulating online is false [1] Employee Statistics - As of December 31, 2024, the company has a total of 8,858 employees, representing an approximate year-on-year growth of 10% [1] - The proportion of employees with senior titles is 26% [1] - Employees holding master's or doctoral degrees account for 52.1% of the workforce [1]

Group 1 - The high-pressure oxygen chamber concept increased by 1.54%, ranking 6th among concept sectors, with five stocks rising, including Aoyang Health, which hit the daily limit, and Yingkang Life, Jinling Pharmaceutical, and International Medicine showing gains of 4.30%, 1.70%, and 0.58% respectively [1][2] - The main capital inflow into the high-pressure oxygen chamber concept was 0.52 billion yuan, with Aoyang Health receiving the highest net inflow of 68.73 million yuan, followed by Yingkang Life and Samsung Medical with net inflows of 11.24 million yuan and 9.36 million yuan respectively [2][3] - Aoyang Health, Yingkang Life, and Tiedean Heavy Industry had the highest net inflow ratios of 7.40%, 3.64%, and 3.00% respectively, indicating strong investor interest [3][4] Group 2 - The top-performing stocks in the high-pressure oxygen chamber concept included Aoyang Health with a daily increase of 10.12% and a turnover rate of 26.84%, while other notable stocks included Yingkang Life and Samsung Medical with increases of 4.30% and 0.17% respectively [3][4] - Stocks that experienced declines included Innovative Medical, Tiedean Heavy Industry, and Weiao Co., with decreases of 1.56%, 0.74%, and 0.68% respectively, indicating some volatility within the sector [1][4]

Group 1 - The core viewpoint of the articles highlights the performance and valuation metrics of Guoji Medical, indicating a recent stock price increase and a notable market capitalization of 11.586 billion yuan [1] - As of March 31, 2025, Guoji Medical has 109,907 shareholders, an increase of 4,413 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in health care services and modern medical technology applications, with its main products spanning medical services, software and IT services, social services, and commodity circulation [1] Group 2 - The latest financial results for Q1 2025 show Guoji Medical achieved a revenue of 999.7 million yuan, a year-on-year decrease of 14.99%, and a net loss of approximately 106.35 million yuan, reflecting a year-on-year decline of 1.37% [1] - The company's gross profit margin stands at 5.21% [1] - In terms of valuation, Guoji Medical has a price-to-earnings (PE) ratio of -45.34 and a price-to-book (PB) ratio of 3.25, with a total market value of 11.586 billion yuan, compared to the industry average PE of 41.42 and PB of 3.52 [2]

Group 1 - The stock price of International Medical (000516) closed at 5.1 yuan on May 30, 2025, with a decrease of 0.2% and a turnover rate of 0.69% [1] - The trading volume was 152,800 shares, with a total transaction amount of 78.0249 million yuan [1] - On the same day, the net outflow of main funds was 4.238 million yuan, while retail investors saw a net inflow of 3.7741 million yuan [2][4] Group 2 - International Medical completed the repurchase and cancellation of 19,304,400 shares, which accounted for 0.8540% of the original total share capital, reducing the total share capital to 2,241,078,315 shares [3] - The total amount spent on the share repurchase was 100.0192 million yuan, with a maximum repurchase price of 9.16 yuan per share [3] - Following the share repurchase, the holding ratio of the controlling shareholder and its concerted actors increased from 31.79% to 32.07%, an increase of 1.28 percentage points, although the number of shares held remained unchanged [2][4]

Core Viewpoint - International Medical (000516) has completed the share repurchase and cancellation process, resulting in an increase in the holding percentage of the controlling shareholder to 32.07% [2][3]. Group 1: Share Repurchase and Cancellation - The company has canceled 19,304,400 shares, which accounts for 0.8540% of the total share capital before cancellation [3][4]. - Following the cancellation, the total share capital has changed from 2,260,382,715 shares to 2,241,078,315 shares [3][4]. - The share repurchase was conducted using self-owned funds, with a total amount not less than RMB 100 million and not exceeding RMB 150 million, and the repurchase price capped at RMB 9.16 per share [3]. Group 2: Shareholding Structure - The controlling shareholder and its concerted parties' holding percentage increased from 31.79% to 32.07% due to the share repurchase [2]. - The total number of shares held by the controlling shareholder remains unchanged at 718,645,251 shares, but the percentage has increased [2]. - The proportion of unrestricted shares held by the controlling shareholder increased from 30.40% to 30.66%, while the proportion of restricted shares increased from 1.40% to 1.41% [2]. Group 3: Market Performance - As of May 30, 2025, International Medical's stock closed at RMB 5.1, down 0.58% from the previous week [1]. - The stock reached a high of RMB 5.14 and a low of RMB 4.95 during the week [1]. - The company's current market capitalization is RMB 11.429 billion, ranking 13th out of 50 in the medical services sector and 1353rd out of 5146 in the A-share market [1].